NASDAQ:MRNS - Marinus Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.87 -0.09 (-1.29 %)
(As of 06/20/2018 04:00 PM ET)
Previous Close$6.87
Today's Range$6.75 - $7.2332
52-Week Range$1.27 - $9.87
Volume543,508 shs
Average Volume953,883 shs
Market Capitalization$283.24 million
P/E Ratio-8.59
Dividend YieldN/A
Beta2.73
Marinus Pharmaceuticals logoMarinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid. The multiple dose forms are intense to maximize the therapeutic range of ganaxolone for adults and pediatric patients. Ganaxolone acts as an anti-seizure, anti-anxiety, and anti-depressive actions; and acts on synaptic and extra synaptic GABAA receptors. The company is also developing ganaxolone for pediatric refractory epilepsy; postpartum depression; and acute epilepsy, which are in Phase II clinical study. In addition, it is developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.

Receive MRNS News and Ratings via Email

Sign-up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MRNS
CUSIPN/A
Phone484-801-4670

Debt

Debt-to-Equity RatioN/A
Current Ratio30.01
Quick Ratio30.01

Price-To-Earnings

Trailing P/E Ratio-8.59
Forward P/E Ratio-10.90
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.43 per share
Price / Book4.80

Profitability

EPS (Most Recent Fiscal Year)($0.80)
Net Income$-18,890,000.00
Net MarginsN/A
Return on Equity-41.07%
Return on Assets-38.45%

Miscellaneous

Employees16
Outstanding Shares40,520,000

Marinus Pharmaceuticals (NASDAQ:MRNS) Frequently Asked Questions

What is Marinus Pharmaceuticals' stock symbol?

Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals Inc (NASDAQ:MRNS) announced its quarterly earnings results on Wednesday, May, 2nd. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.16) by $0.01. View Marinus Pharmaceuticals' Earnings History.

When is Marinus Pharmaceuticals' next earnings date?

Marinus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Marinus Pharmaceuticals.

What price target have analysts set for MRNS?

6 Wall Street analysts have issued 1 year price objectives for Marinus Pharmaceuticals' stock. Their forecasts range from $11.00 to $33.00. On average, they anticipate Marinus Pharmaceuticals' share price to reach $18.3333 in the next twelve months. View Analyst Ratings for Marinus Pharmaceuticals.

Who are some of Marinus Pharmaceuticals' key competitors?

Who are Marinus Pharmaceuticals' key executives?

Marinus Pharmaceuticals' management team includes the folowing people:
  • Mr. Christopher Michael Cashman, Exec. Chairman, Chief Exec. Officer and Pres (Age 61)
  • Mr. Edward F. Smith, CFO, VP, Treasurer & Sec. (Age 47)
  • Dr. Lorianne K. Masuoka M.D., Chief Medical Officer (Age 57)
  • Ms. Lisa M. Caperelli, Exec. Director of Investor & Strategic Relations
  • Dr. Kimberly A. McCormick PharmD, Head of Regulatory Affairs

Has Marinus Pharmaceuticals been receiving favorable news coverage?

Media coverage about MRNS stock has been trending somewhat positive on Wednesday, according to Accern. The research group identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Marinus Pharmaceuticals earned a news sentiment score of 0.18 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 47.89 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are Marinus Pharmaceuticals' major shareholders?

Marinus Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (4.12%), BlackRock Inc. (1.57%), Millennium Management LLC (1.43%), Artal Group S.A. (1.23%), JPMorgan Chase & Co. (0.24%) and Barclays PLC (0.15%). Company insiders that own Marinus Pharmaceuticals stock include Anand Mehra, Bain Capital Life Sciences Inv, Christopher Michael Cashman, Edward F Smith and Vii Lp Canaan. View Institutional Ownership Trends for Marinus Pharmaceuticals.

Which institutional investors are selling Marinus Pharmaceuticals stock?

MRNS stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Millennium Management LLC, A.R.T. Advisors LLC and BlackRock Inc.. Company insiders that have sold Marinus Pharmaceuticals company stock in the last year include Bain Capital Life Sciences Inv, Christopher Michael Cashman and Edward F Smith. View Insider Buying and Selling for Marinus Pharmaceuticals.

Which institutional investors are buying Marinus Pharmaceuticals stock?

MRNS stock was bought by a variety of institutional investors in the last quarter, including Artal Group S.A., JPMorgan Chase & Co. and Barclays PLC. View Insider Buying and Selling for Marinus Pharmaceuticals.

How do I buy shares of Marinus Pharmaceuticals?

Shares of MRNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Marinus Pharmaceuticals' stock price today?

One share of MRNS stock can currently be purchased for approximately $6.87.

How big of a company is Marinus Pharmaceuticals?

Marinus Pharmaceuticals has a market capitalization of $283.24 million. The biopharmaceutical company earns $-18,890,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Marinus Pharmaceuticals employs 16 workers across the globe.

How can I contact Marinus Pharmaceuticals?

Marinus Pharmaceuticals' mailing address is 170 N. Radnor Chester Rd Suite 250, Radnor PA, 19087. The biopharmaceutical company can be reached via phone at 484-801-4670 or via email at [email protected]


MarketBeat Community Rating for Marinus Pharmaceuticals (MRNS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  180 (Vote Outperform)
Underperform Votes:  155 (Vote Underperform)
Total Votes:  335
MarketBeat's community ratings are surveys of what our community members think about Marinus Pharmaceuticals and other stocks. Vote "Outperform" if you believe MRNS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRNS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.